Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137082 · ClinicalTrials.gov registry record · Phase 1
Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
A Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03137082: Completed Phase 1 study, sponsored by Stony Brook University.
NCT03137082 is a Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03137082, a Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.
Primary Outcome
Percentage of days abstinent across the 12-week trial was calculated using the Timeline follow Back.
Interventions
- DRUG Guanfacine XR 3mgs/daily
- DRUG Placebo (for guanfacine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
What the finished NCT03137082 record still lists
NCT03137082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Guanfacine XR 3mgs/daily is the first listed.
NCT03137082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03137082 about?
NCT03137082 is a clinical study titled "Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)". Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Exten...
What is the current status of trial NCT03137082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-07-12. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03137082?
The interventions under investigation include: Guanfacine XR 3mgs/daily (DRUG), Placebo (for guanfacine) (DRUG).
Who is sponsoring clinical trial NCT03137082?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03137082's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI